Imaging Biometrics Limited
(“IBAI” or the “Company”)
AMENDMENT TO NOTICE OF ANNUAL GENERAL MEETING
The Company notes an error to RNS 12 May 2026 (RNS Number: 0280E), that incorrectly stated that the ordinary shares of £0.01 will be sub-divided into one ordinary share of £0.0005. The ordinary shares of £0.01 will in fact be sub-divided into one ordinary share of £0.005.
The corrected Notice of AGM will shortly be available at https://imagingbiometrics.com/. All other resolutions have not been amended.
The corrected announcement reads:
Imaging Biometrics Limited, the Main Market listed healthcare technology group, is pleased to announce that its Annual General Meeting (“AGM”) will be held at IFC5, St Helier, Jersey, JE1 1ST on 3 June 2026 at 10:00 am.
The Notice of AGM includes, inter alia, details of a proposed share sub-division whereby each current ordinary share of £0.01 will be sub-divided into one ordinary share of £0.005. The number of ordinary shares in issue will not change and will remain at 246,709,789 ordinary shares of £0.005, assuming that the sub-division resolution is passed at the AGM.
A form of proxy will accompany the Notice of AGM and the Noice of AGM will shortly be available at https://imagingbiometrics.com/
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
|
Imaging Biometrics Limited Trevor Brown / Brett Skelly / Michael Schmainda / John Richardson Tel: 020 7469 0930 |
|
AlbR Capital Limited (Corporate Broker) Lucy Williams / Duncan Vasey Tel: 020 7220 9797 |
Notes to Editors
About Imaging Biometrics Limited
Imaging Biometrics Limited is an LSE-listed healthcare technology group focused on quantitative neuroimaging software and organ-on-a-chip technology. Its principal subsidiary, Imaging Biometrics LLC, is a world leader in advanced MRI analysis software used in the assessment of brain tumours, with products distributed globally including through a commercial agreement with GE HealthCare. Kirkstall Limited, acquired by IBAI in October 2025, develops the Quasi Vivo® organ-on-a-chip platform for use in pharmaceutical research, toxicology testing and disease modelling.
About Kirkstall Limited
Kirkstall Limited is a biotechnology company specialising in microfluidic organ-on-a-chip systems. Its Quasi Vivo® platform enables cells to be maintained under physiological flow conditions that closely mimic the human body, providing pharmaceutical and academic researchers with more predictive and human-relevant in vitro models. Kirkstall has an established international distributor network spanning the United States, China and South Korea.
About Nottingham Trent University
NTU owns two Queen’s Anniversary Prizes for outstanding achievements in research (2015, 2021). The Research Excellence Framework (2021) classed 83% of NTU’s research activity as either world-leading or internationally excellent. Professor Gareth Cave and his team in the School of Science and Technology work at the interface of pharmaceutical science and biomedical engineering.
About the NC3Rs/BBSRC Business Interaction Voucher Scheme
The Business Interaction Voucher scheme is a joint funding initiative from the NC3Rs and BBSRC designed to support collaboration between academic researchers in the NC3Rs network and commercial partners. The scheme aims to accelerate the development and adoption of human-relevant, animal-free research technologies.